Subsequent gene expression profiling studies of ER-positive breast cancers demonstrated that this group is still heterogeneous in ER expression levels and proliferation-related genes [6, 7], which is associated with clinical outcomes and treatment response. The gene discussed is ESR1; the disease is breast carcinoma.